Modification of pyrimidine derivatives from antiviral agents to antitumor agents

Hiroyuki Kimura, Takahiro Katoh, Tetsuya Kajimoto, Manabu Node, Masakatsu Hisaki, Yoshikazu Sugimoto, Tetsuo Majima, Yoshimasa Uehara, Takao Yamori

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

2,4-Diaminopyrimidine derivatives, that were originally developed as antiviral agents, were modified to antitumor agents by: i) introducing an amino group at C-5 on the pyrimidine ring, ii) changing the alkyl group and the ring size of the cycloalkyl group on the β-position of the ω- hydroxyalkylamino group, iii) replacing the phenylalkyl group on the cycloalkyl group with the 3,4,5-trimethoxyphenylalkyl group, iv) the esterification of the primary alcohol with diethyl phosphate and v) introducing the thiomethyl group at C-2 on the pyrimidine ring. Among the 21 compounds prepared, 6, which has cyclobutyl at the β-position, exhibited potent activity towards P-388 leukemia. In addition, 14, with methoxyl groups on the phenyl ring and 17, with the thiomethyl group on the pyrimidine ring, showed specific inhibition for the EGFR protein kinase. Moreover, 15 and 16, which carry the diethyl phosphoryl group on the primary alcohol, exhibited inhibitory activity towards P-glycoprotein.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalAnticancer research
Volume26
Issue number1 A
Publication statusPublished - 2006 Jan 1
Externally publishedYes

Keywords

  • Antitumor agents
  • Antiviral agents
  • Pyrimidine derivatives

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Modification of pyrimidine derivatives from antiviral agents to antitumor agents'. Together they form a unique fingerprint.

  • Cite this

    Kimura, H., Katoh, T., Kajimoto, T., Node, M., Hisaki, M., Sugimoto, Y., Majima, T., Uehara, Y., & Yamori, T. (2006). Modification of pyrimidine derivatives from antiviral agents to antitumor agents. Anticancer research, 26(1 A), 91-97.